Detailed price information for Bio-Path Holdings (BPTH-Q) from The Globe and Mail including charting and trades.

Detailed price information for Bio-Path Holdings (BPTH-Q) from The Globe and Mail including charting and trades.

Researchers determined discontinuing BTK inhibitors appears to be more common than discontinuing venetoclax plus obinutuzumab for older patients with CLL.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Patients treated in community settings were more likely to be older, less likely to be White, and had worse survival rates, ...

Bio-Path (BPTH) provided an update from the company’s ongoing Phase 1/1b clinical trial evaluating BP1002 for the treatment of ...

Chemicals and materials maker DuPont (DD) is rallying 7% after posting stronger-than-expected fourth quarter financial ...

Kuick Research Report Highlights Ongoing Developments In Molecular Switches Application Therapeutic Targets & Drug Delivery ...

Venetoclax, a selective Bcl-2 inhibitor, has proven effective in chronic lymphocytic leukemia (CLL), but genetic mutations or ...

Disparate pathogenic mechanisms complicate precision-medicine efforts to treat diffuse large B-cell lymphoma (DLBCL), the most common lymphoma diagnosis. Though potentially curable with frontline ...